Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-01-05 @ 5:30 PM
Study NCT ID:
NCT05355168
Status:
COMPLETED
Last Update Posted:
2024-12-31
First Post:
2022-04-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D064420', 'term': 'Drug-Related Side Effects and Adverse Reactions'}, {'id': 'D000077277', 'term': 'Esophageal Squamous Cell Carcinoma'}], 'ancestors': [{'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D018307', 'term': 'Neoplasms, Squamous Cell'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000631724', 'term': 'camrelizumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'To enroll 35 initially inoperable patients with locally advanced esophageal squamous cell carcinoma to receive neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 35}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-11-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-12', 'completionDateStruct': {'date': '2024-03-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-12-28', 'studyFirstSubmitDate': '2022-04-16', 'studyFirstSubmitQcDate': '2022-04-26', 'lastUpdatePostDateStruct': {'date': '2024-12-31', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-05-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '1-year progression free survival (PFS) rate', 'timeFrame': '0 month post neoadjuvant treatment', 'description': '1-year progression free survival (PFS) rate'}], 'secondaryOutcomes': [{'measure': 'Rate of adverse events', 'timeFrame': '1 to 2years', 'description': 'Rate of adverse events (CTCAE V4.0)'}, {'measure': 'Pathological complete remission rate', 'timeFrame': '0 month post surgery', 'description': 'Pathological complete remission rate (CAP Cancer Protocol for Esophageal Carcinoma)'}, {'measure': '1-, 2-year overall survival rate .', 'timeFrame': '1 to 2years', 'description': '1-, 2-year overall survival rate .'}, {'measure': 'Major pathological remission rate', 'timeFrame': '0 month post surgery', 'description': 'Major pathological remission rate (CAP Cancer Protocol for Esophageal Carcinoma)'}, {'measure': 'surgical conversion rate', 'timeFrame': '0 month post neoadjuvant', 'description': 'surgical conversion rate'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Esophageal squamous cell carcinoma', 'neoadjuvant chemoradiotherapy', 'nimotuzumab', 'camrelizumab'], 'conditions': ['Toxicity, Drug']}, 'referencesModule': {'references': [{'pmid': '40834785', 'type': 'DERIVED', 'citation': 'He Y, Liu H, Li X, Wang J, Wu H, Zhou H, Wang X, Cheng J, Ma J, Mei X, Tian J, Qian D. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. Eur J Cancer. 2025 Oct 1;228:115717. doi: 10.1016/j.ejca.2025.115717. Epub 2025 Aug 15.'}]}, 'descriptionModule': {'briefSummary': 'Neoadjuvant chemoradiotherapy followed by surgery has been the standard modality for locally advance esophageal carcinoma. According to CROSS study, the pathological complete remission rate achieved by paclitaxel and carboplatin with 41.4 Gy/23f was 49% for esophageal squamous cell carcinoma. But the 10-year overall survival rate was only 38%. How to increase the overall survival of esophageal carcinoma is a pivotal task. Both of Camrelizumab and Nimotuzumab have been demonstrated to be efficacious in the neoadjuvant treatment for esophageal squamous cell carcinoma in some small sample-size trials. Therefore, this trial is designed to combine adjuvant chemoradiotherapy with Camrelizumab and Nimotuzumab for resectable \\& potentially resectable locally advanced esophageal squamous cell carcinoma and explore the safety and primary efficacy of such combination.', 'detailedDescription': 'Trial Title Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab for initially inoperable patients with locally advanced esophageal squamous cell carcinoma: A Prospective, One-arm, Phase II study (NCRCN) Trial Objective To explore the safety and primary efficacy of neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab for initially inoperable patients with locally advanced esophageal squamous cell carcinoma.\n\nTrial Design: To enroll 35 patients with initially inoperable patients with locally advanced esophageal squamous cell carcinoma to receive neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery.\n\nStaging Examination before Adjuvant Treatment: a. ECOG scoring. b. PET-CT, Upper GI endoscopy \\& endoscopic ultrasound and barium swallow (preferred), or chest contrast CT, abdominal ultrasonography, bone scan, Upper GI endoscopy \\& endoscopic ultrasound and barium swallow. c. Bronchoscopy for patients with suspicious invasion into trachea or bronchus. d. Pulmonary function test.\n\nAdjuvant chemoradiotherapy Radiotherapy CT Simulation: CT with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm from lower margin of mandibular to lower margin of L2. Thermal mask is recommended.\n\nDelineation of Targets: Involved field irradiation is the general principle. Gross Tumor Volume (GTV) is the primary esophageal tumor and the metastatic lymph node. The Clinical Target Volume (CTV) provided a proximal and distal margin of 3 cm and a 0.8 cm radial margin around the primary esophageal tumor and a proximal and distal margin of 1 cm and a 0.8 cm radial margin around the metastatic lymph nodes. The Planning Target Volume (PTV) was defined as an 8-mm margin of the CTV for tumor motion and set-up variations.\n\nPrescription Dose: 41.4 Gy/23f to PTV. Dosimetric Limitation of Organ at Risk: 95% prescription dose should cover 100% PTV and 95% PTV should receive 100% prescription dose. Total Lung: V20\\<25%, Dmean\\<13Gy, V5\\<50%. Spinal Cord: Dmax\\<45Gy. Heart: V30\\<40%, Dmean\\<25Gy.\n\nTreatment Implementation: Radiotherapy is implemented every day. Cone-beam CT should utilized every week to minimize set-up error.\n\nChemotherapy nab-paclitaxel 50mg/m2+Carboplatin AUC=2 qw×5c, Nimotuzumab 200mg q3w×2c, Camrelizumab 200mg q3w×2c.\n\nRestaging Examination before Surgery: a. ECOG scoring. b. PET-CT and barium swallow (preferred), or chest contrast CT, abdominal ultrasonography, bone scan and barium swallow. c. Pulmonary function test.\n\nRestaging is aiming to exclude patients with disease progression after neoadjuvant treatment.\n\nSurgery Surgery is scheduled for 4 to 6 weeks after completion of adjuvant treatment. McKeown or Ivor-Lewis esophagectomy, including two-field lymphadenectomy with total mediastinal lymph node dissection, is performed. The dissection of left and right recurrent laryngeal nerve nodes is mandatory.\n\nFollow-up: Patients should be follow-up every three months right after the completion of surgery to 2 years after surgery. Then follow-up every half year is allowed to 5 years after surgery. After 5 years, follow-up every year is appropriate. In follow-up, chest contrast CT and abdominal ultrasonography should be implemented. Endoscopy should be undertaken every year for all patients.\n\nPrimary Endpoint: 1-year progression free survival (PFS) rate. Secondary Endpoint: Pathological complete remission rate and major pathological remission rate (CAP Cancer Protocol for Esophageal Carcinoma). Surgical conversion rate, Rate of adverse events (CTCAE V4.0), 2-year progression free survival (PFS) rate.1-year, 2-year overall survival rates (OS) .'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* 18-75 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-1;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0-1a (AJCC 8th) confirmed by radiological examination;\n* Initially inoperable at initial diagnosis confirmed by thoracic surgeons;\n* No esophageal hemorrhage and no esophageal fistula at initial diagnosis;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy, camrelizumab and nimotuzumab;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 75 years old;\n* ECOG\\>1;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* Presence of esophageal hemorrhage and esophageal fistula at initial diagnosis;\n* Previous treatment of chemotherapy, radiotherapy, immune therapy and other treatment;\n* Contraindications for chemoradiotherapy, camrelizumab and nimotuzumab;\n* No signature of inform consent.'}, 'identificationModule': {'nctId': 'NCT05355168', 'briefTitle': 'Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Anhui Provincial Hospital'}, 'officialTitle': 'Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, One-arm, Phase II Study (NCRCN)', 'orgStudyIdInfo': {'id': '2021-ky238'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Neoadjuvant treatment', 'description': 'Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab', 'interventionNames': ['Drug: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery']}], 'interventions': [{'name': 'neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery', 'type': 'DRUG', 'description': 'neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery', 'armGroupLabels': ['Neoadjuvant treatment']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'Anhui Provicial Hospital', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Anhui Provincial Hospital', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Dong Qian', 'investigatorAffiliation': 'Anhui Provincial Hospital'}}}}